Board of Directors


Anne Hyland
Non-executive Director

Anne Hyland was appointed a non-executive director in June 2013 and Chairman of the Audit Committee on 1 August 2013. She is CFO of Kymab Ltd, a biopharmaceutical company funded by the Wellcome Trust and the Bill & Melinda Gates Foundation, and (from 1 January 2018) was appointed a non-executive director of AIM-listed Clinigen Group plc, a global pharmaceutical and services company, where she is also the chairman of the audit committee. Prior to her current executive role, she was CFO and company secretary of BBI Diagnostics Group Ltd and FTSE-listed Vectura Group plc. Previous senior finance positions held by her include at then FTSE 100 Celltech Group plc (including director of corporate finance), Medeva plc and KPMG. She is a chartered accountant (FCA), a corporate tax adviser (CTA – AITI) and holds a degree in business studies from Trinity College, Dublin. She was a trustee of the charity Sustrans (sustainable transport), which developed the UK National Cycle Network, between January 2012 and December 2017.

Company Secretary


    Principal role of the Board
  • Set corporate objectives and the strategic direction of the Group;
  • Provide leadership and direction to management and monitor corporate and business performance;
  • Set high standards in business conduct and ethics, and in business, employee and community relations;
  • Set policy and provide oversight for governance, financial control and risk management, and health, safety and environmental performance; and
  • Ensure adequate funding for the Group to invest in growth.
Matters Reserved for The Board (48 KB)